trading halt

Request for Trading Halt for Antisense Therapeutics Limited
In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).
In requesting the trading halt, the Company provides the following information:
? The trading halt is requested pending the release of an update on the status of the ATL1103 phase II clinical trial;
? Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until an announcement is made to the market; and
? The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.